WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive: In a study conducted by Oliver Henke et al. [18]: it was observed that Imatinib’s utilization in the management of CML radically altered the way this disease was addressed and spurred the advent of additional potent targeted protein kinase inhibitors.